Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Erlotinib, and Temozolomide in Recurrent Glioblastoma Multiforme
NCT01110876Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2011
- Primary completion
- Jul 2014
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in glioblastoma multiforme (GBM), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2011; status: terminated.
02
Drugs
vorinostat
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01110876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110876.